|
rs1800625
|
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b><i>RAGE</i> gene SNP rs1800625 was significantly associated with gastric cancer risk, and rs1800625 and rs184003 were related to tumor clinical stage, indicating that <i>RAGE</i> gene may be a gastric cancer-susceptibility gene.
|
30719146 |
2019 |
|
rs4072037
|
|
Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
<b>Conclusion:</b> MUC1 rs4072037 polymorphism is associated with decreased cancer risk and can probably be used as a tumor marker, especially for gastric cancer and for Asians.
|
30271495 |
2018 |
|
rs184003
|
|
Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
<b>Conclusions:</b><i>RAGE</i> gene SNP rs1800625 was significantly associated with gastric cancer risk, and rs1800625 and rs184003 were related to tumor clinical stage, indicating that <i>RAGE</i> gene may be a gastric cancer-susceptibility gene.
|
30719146 |
2019 |
|
rs2498804
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
<b>Results:</b> In an analysis of 97 LARC patients, the G/T+G/G genotype of AKT1:rs2498804 was associated with an increased tumor response rate (adjusted OR = 2.909, 95% confidence interval (CI), 1.127-7.505, P = 0.027).
|
29581786 |
2018 |
|
rs121434569
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>EGFR</i> T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method.
|
28476851 |
2017 |
|
rs1057519697
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>In vitro</i> prostate cell line/organoid models were generated by lentiviral-mediated expression of ALK and ALK F1174C and assessed for response to ALK inhibitors crizotinib and alectinib.<b>Results:</b> NGS analysis of the primary tumor and ctDNA of a 39-year-old patient with refractory SSCP identified <i>ALK</i> F1174C mutation.
|
29559559 |
2018 |
|
rs2267437
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
(XRCC6) rs2267437 appeared as a risk factor for developing more aggressive PCa tumors.
|
26754263 |
2016 |
|
rs104893829
|
|
Neoplasms
|
|
0.720 |
GeneticVariation
|
BEFREE |
1) Clinical evaluation of known variant carriers: We evaluated a family of five VHL p.P81S carriers, as well as the clinical characteristics of all the p.P81S carriers reported in the literature; 2) Evaluation of tumor tissue via genetic analysis, histology, and immunohistochemistry (IHC); 3) Assessment of the variant's impact on protein structure and function, using multiple databases, in silico algorithms, and reports of functional studies.
|
28503092 |
2017 |
|
rs727503094
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
44% of the tumors were positive for G12D, 20% for G12V, and 10% for G12C.
|
27591291 |
2016 |
|
rs121913529
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
44% of the tumors were positive for G12D, 20% for G12V, and 10% for G12C.
|
27591291 |
2016 |
|
rs104894230
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
44% of the tumors were positive for G12D, 20% for G12V, and 10% for G12C.
|
27591291 |
2016 |
|
rs9503518
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
77.2% of patients were homozygote for genotype rs9503518-AA and they most frequently had histological grade 2 and 3 tumors.
|
29703252 |
2018 |
|
rs781172058
|
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
801A carrier status (801G/A, 801A/A) was found to be associated with a higher PBB count compared with 801G/G homozygous patients (P=0.031) and higher frequency of extramedullar tumor sites (odds ratio 2.92, 95% confidence interval 1.18-7.21, P=0.018).
|
16818471 |
2006 |
|
rs766914563
|
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
801A carrier status (801G/A, 801A/A) was found to be associated with a higher PBB count compared with 801G/G homozygous patients (P=0.031) and higher frequency of extramedullar tumor sites (odds ratio 2.92, 95% confidence interval 1.18-7.21, P=0.018).
|
16818471 |
2006 |
|
rs371074389
|
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
801A carrier status (801G/A, 801A/A) was found to be associated with a higher PBB count compared with 801G/G homozygous patients (P=0.031) and higher frequency of extramedullar tumor sites (odds ratio 2.92, 95% confidence interval 1.18-7.21, P=0.018).
|
16818471 |
2006 |
|
rs113488022
|
|
Neoplasms
|
|
0.800 |
GeneticVariation
|
BEFREE |
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
|
16960555 |
2007 |
|
rs121913377
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
|
16960555 |
2007 |
|
rs1418810723
|
|
Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.
|
16960555 |
2007 |
|
rs397507828
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Tumor DNA of a serous borderline ovarian tumor (sBOT) of a 55-year-old female carrier of a pathogenic BRCA2 mutation (6085G>T) was analyzed for loss of heterozygosity (LOH) of BRCA2.
|
17386038 |
2007 |
|
rs121913412
|
|
Neoplasms
|
|
0.070 |
GeneticVariation
|
BEFREE |
Tumor DNA analysis revealed a heterozygous ACC-to-GCC missense mutation in codon 41 (T41A) and a TCT-to-CCT missense mutation in codon 45 (S45P) of exon 3 of the beta-catenin gene that was confirmed at the cDNA level.
|
18419788 |
2008 |
|
rs201362232
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Tumor DNA analysis revealed a heterozygous ACC-to-GCC missense mutation in codon 41 (T41A) and a TCT-to-CCT missense mutation in codon 45 (S45P) of exon 3 of the beta-catenin gene that was confirmed at the cDNA level.
|
18419788 |
2008 |
|
rs1356757839
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Tumor DNA analysis revealed a heterozygous ACC-to-GCC missense mutation in codon 41 (T41A) and a TCT-to-CCT missense mutation in codon 45 (S45P) of exon 3 of the beta-catenin gene that was confirmed at the cDNA level.
|
18419788 |
2008 |
|
rs121913407
|
|
Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
Tumor DNA analysis revealed a heterozygous ACC-to-GCC missense mutation in codon 41 (T41A) and a TCT-to-CCT missense mutation in codon 45 (S45P) of exon 3 of the beta-catenin gene that was confirmed at the cDNA level.
|
18419788 |
2008 |
|
rs1459684511
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Tumor DNA analysis revealed a heterozygous ACC-to-GCC missense mutation in codon 41 (T41A) and a TCT-to-CCT missense mutation in codon 45 (S45P) of exon 3 of the beta-catenin gene that was confirmed at the cDNA level.
|
18419788 |
2008 |
|
rs138551214
|
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Tumor tissue from the G787R variant case manifested loss of heterozygosity, with loss of the wild-type allele, supporting a tumor suppressor role for EPHB2 in rare colorectal cancer cases.
|
18682749 |
2008 |